(-0.04%) 5 145.00 points
(-0.05%) 38 541 points
(-0.09%) 17 889 points
(0.51%) $83.05
(2.56%) $2.08
(-1.38%) $2 325.10
(-2.55%) $26.96
(-1.30%) $949.00
(0.00%) $0.932
(0.30%) $11.02
(0.12%) $0.797
(-0.02%) $93.28
0.21% HKD 4.75
Live Chart Being Loaded With Signals
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics...
Stats | |
---|---|
Volumen de hoy | 1.32M |
Volumen promedio | 2.75M |
Capitalización de mercado | 4.58B |
EPS | HKD0 ( 2023-08-23 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -19.79 |
ATR14 | HKD0.0190 (0.40%) |
Volumen Correlación
Alphamab Oncology Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alphamab Oncology Correlación - Moneda/Commodity
Alphamab Oncology Finanzas
Annual | 2023 |
Ingresos: | HKD218.77M |
Beneficio Bruto: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2023 |
Ingresos: | HKD218.77M |
Beneficio Bruto: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2022 |
Ingresos: | HKD166.85M |
Beneficio Bruto: | HKD122.64M (73.50 %) |
EPS: | HKD-0.350 |
FY | 2021 |
Ingresos: | HKD146.02M |
Beneficio Bruto: | HKD142.99M (97.93 %) |
EPS: | HKD-0.444 |
Financial Reports:
No articles found.
Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico